KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Gross Margin (2016 - 2025)

Historic Gross Margin for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to 82.91%.

  • Eli Lilly's Gross Margin rose 18900.0% to 82.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 83.03%, marking a year-over-year increase of 21200.0%. This contributed to the annual value of 81.31% for FY2024, which is 20600.0% up from last year.
  • According to the latest figures from Q3 2025, Eli Lilly's Gross Margin is 82.91%, which was up 18900.0% from 84.27% recorded in Q2 2025.
  • Over the past 5 years, Eli Lilly's Gross Margin peaked at 84.27% during Q2 2025, and registered a low of 71.02% during Q2 2021.
  • Moreover, its 5-year median value for Gross Margin was 78.87% (2021), whereas its average is 78.68%.
  • As far as peak fluctuations go, Eli Lilly's Gross Margin tumbled by -68700bps in 2021, and later surged by 69300bps in 2022.
  • Over the past 5 years, Eli Lilly's Gross Margin (Quarter) stood at 74.37% in 2021, then grew by 6bps to 78.8% in 2022, then increased by 3bps to 80.88% in 2023, then grew by 2bps to 82.24% in 2024, then grew by 1bps to 82.91% in 2025.
  • Its Gross Margin was 82.91% in Q3 2025, compared to 84.27% in Q2 2025 and 82.53% in Q1 2025.